These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16333583)

  • 21. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.
    Pietrasik G; Goldenberg I; McNitt S; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2007 Feb; 18(2):181-4. PubMed ID: 17338766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arrhythmia detection in single- and dual-chamber implantable cardioverter defibrillators: the more leads, the better?
    Francia P; Balla C; Uccellini A; Cappato R
    J Cardiovasc Electrophysiol; 2009 Sep; 20(9):1077-82. PubMed ID: 19500231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction: 14 years after MADIT.
    Franqui-Rivera H; Sotomonte JC
    P R Health Sci J; 2011 Jun; 30(2):78-83. PubMed ID: 21682151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study.
    Proclemer A; Muser D; Campana A; Zoni-Berisso M; Zecchin M; Locatelli A; Brieda M; Gramegna L; Santarone M; Chiodi L; Mazzone P; Rebellato L; Facchin D
    Int J Cardiol; 2013 Sep; 168(2):1416-21. PubMed ID: 23287697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention.
    Al-Khatib SM; Sanders GD; Carlson M; Cicic A; Curtis A; Fonarow GC; Groeneveld PW; Hayes D; Heidenreich P; Mark D; Peterson E; Prystowsky EN; Sager P; Salive ME; Thomas K; Yancy CW; Zareba W; Zipes D
    Am Heart J; 2008 Oct; 156(4):613-22. PubMed ID: 18926144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
    Nanthakumar K; Epstein AE; Kay GN; Plumb VJ; Lee DS
    J Am Coll Cardiol; 2004 Dec; 44(11):2166-72. PubMed ID: 15582314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures.
    Hauptman PJ; Swindle JP; Masoudi FA; Burroughs TE
    Circ Cardiovasc Qual Outcomes; 2010 Mar; 3(2):204-11. PubMed ID: 20197509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
    Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
    J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II).
    Greenberg H; Case RB; Moss AJ; Brown MW; Carroll ER; Andrews ML;
    J Am Coll Cardiol; 2004 Apr; 43(8):1459-65. PubMed ID: 15093884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.
    Desai AD; Burke MC; Hong TE; Kim S; Salem Y; Yong PG; Knight BP
    J Cardiovasc Electrophysiol; 2006 May; 17(5):486-90. PubMed ID: 16684019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is an electrophysiological study always necessary before defibrillator implantation?].
    Bänsch D; Antz M
    Herz; 2005 Mar; 30(2):119-22. PubMed ID: 15875100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ICD therapy in coronary artery disease. A reappraisal in 2005.
    Grönefeld G; Manegold J; Israel CW; Hohnloser SH
    Herz; 2005 Mar; 30(2):82-6. PubMed ID: 15875095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Device therapies in the post-myocardial infarction patient with left ventricular dysfunction.
    Kadish AH; Reiffel JA; Naccarelli GV; DiMarco JP
    Am J Cardiol; 2008 Sep; 102(5A):29G-37G. PubMed ID: 18722189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comparison of ICD implantations in the United States versus Italy.
    Greenberg SM; Epstein AE; Deering T; Goldman DS; Ghidina M; Neason C; Proclemer A
    Pacing Clin Electrophysiol; 2007 Jan; 30 Suppl 1():S143-6. PubMed ID: 17302692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
    Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
    J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
    Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up and risk assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy: personal experience from different primary and tertiary centres.
    Peters S
    J Cardiovasc Med (Hagerstown); 2007 Jul; 8(7):521-6. PubMed ID: 17568286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.